Summary
PRA Health Sciences supported 2 multiple myeloma clinical trials, a Phase III and a “rollover,” for a large biotech client. This management contract was one of the largest on record in the ongoing research for multiple myeloma treatment. PRA’s clinical team provided enhanced communication and site support, enabling PRA to streamline regulatory document collection to quickly activate sites. Approved by the FDA after a 4-month accelerated approval process, the drug is the first in a new class of anti-cancer agents called proteasome inhibitors.
Register to download
PRA Leads Novel Multiple Myeloma Drug Development
You may also be interested in:
Case Study
PRA Cool Under Deadline Pressure
PRA was selected to perform a Phase II colorectal cancer trial due to our knowledge from previous colorectal studies as well as our evidence-based…
page
Executive Leadership
Since our inception in 1976, PRA has amassed a level of expertise that has enabled us to conduct complex global clinical trials across all…
Case Study
IIT Program Management Case Study
6+ year relationship with a large biopharma company that needed to change the operating model for their investigator-initiated trials (IIT), in part…